Amgen Announces Evolocumab Reduces Risk of Cardiovascular Events
Amgen announced today that the FOURIER trial met its primary and secondary endpoints in evaluating whether evolocumab reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) without new safety issues. Amgen also announced that the EBBINGHAUS trial revealed no difference in cognitive function between evolocumab and placebo. Detailed results will be released at the American College of Cardiology meeting in March. For additional information, and to read the Amgen press release, click here.